For people who are not able or willing to get an mRNA vaccine, a protein subunit vaccine will be made available. The plan was to use the protein subunit vaccine made by HIPRA (Bimermax JN.1), but the European Medicines Agency (EMA) has not yet completed its assessment. EMA approval is necessary before the vaccine can be used. It is not yet known when the EMA will be reaching its decision. Keep an eye on this RIVM page for updates on when the protein subunit vaccine is available.